Kuehn Law Encourages Investors of Tempus AI, Inc. to Contact Law Firm

New York, New York--(Newsfile Corp. - September 4, 2025) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Tempus AI, Inc. (NASDAQ: TEM) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Insiders at Tempus AI caused the company to brand itself as an AI company despite having little history of generating significant revenues from AI solutions; instead, the Company generated most of its revenues from acquisitions, genomic testing and data licensing agreements. Insiders repeatedly claimed that the contract value and quality of its data licensing agreements with life science companies were secure and expanding. The Company often reported on its relationship with long-term customer AstraZeneca as an example. Importantly, Tempus announced an expanding contract with AstraZeneca via a joint venture between the Company, AstraZeneca and Pathos AI. The Company similarly announced a joint venture with SoftBank as a way to generate revenue growth by entering the Japanese market. Tempus additionally claimed high revenue potential for Ambry Genetics ("Ambry"), a target it acquired. The Company claimed that Ambry's accelerated growth was on account of its strong relationships with health care providers.

If you currently own TEM and purchased prior to August 6, 2024 please contact Justin Kuehn, Esq. here, by email at justin@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™

For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265155